Home Compare PLTR vs ZEAL.CO
Stock Comparison · Valuation-led comparison

Palantir Technologies vs Zealand Pharma A/S: Which Stock Looks Stronger in 2026?

Zealand Pharma A/S leads structurally, with valuation as the clearest single gap between the two profiles. Palantir Technologies does not offset that deficit through any equally strong structural edge elsewhere. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Valuation still does most of the heavy lifting in this comparison. Zealand Pharma A/S leads by 24 points on the overall comparison score.

Trajectory Similarity
0.64
Moderately similar
Peer-set rank: #16
within Palantir Technologies Inc.'s functional peer set

This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.

The pair shares a valid long-term profile match, but the trajectories are not especially close.

The strongest overlap appears in investment intensity and margin trend.

Similarity drivers
investment intensitymargin trend
What reduces the match
recent revenue growth
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
PLTR
Palantir Technologies Inc.
60
Peer-Score
Signal qualityHigh
vs
ZEAL.CO
Zealand Pharma A/S
84
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Pricing shapes this comparison more than a broad operating gap.

Dimension spread: PLTR vs ZEAL.CO Profitability 96 100 Stability 41 36 Valuation 9 88 Growth 100 100 PLTR ZEAL.CO
Gap Ranking
#1 Valuation +79
#2 Stability +5
#3 Profitability +4
#4 Growth
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for PLTR and ZEAL.CO Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer PLTRZEAL.CO Relative valuation Structural strength

Structure stays fairly close here, while current pricing still looks more supportive for Zealand Pharma A/S.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Valuation
On valuation, Zealand Pharma A/S ranks near the top of the group; Palantir Technologies Inc. sits in the weaker half.
Valuation — Dominant Gap
PLTR
9
ZEAL.CO
88
Gap+79in favour of ZEAL.CO

The multiple-based pricing edge comes from a forward P/E that is 21.1 turns lower.

What keeps the gap from being one-sided

Palantir Technologies Inc. still shows lower market-fundamental divergence, which keeps the wider picture mixed rather than completely one-sided.

What this means for the comparison

The main edge on valuation is clear, but the broader result still comes with a real counterweight.

Explore full peer positioning in AssetNext

Break down the PLTR vs ZEAL.CO comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar valuation-driven comparisons

Explore how PLTR and ZEAL.CO each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.